Mandate

Vinge has advised Cameco in connection with its USD 7.8bn acquisition of Westinghouse Electric Company

Vinge, alongside Covington & Burling LLP, has advised Cameco Corporation in their acquisition of Westinghouse Electric Company in a deal valued at USD 7.875 billion. Cameco together with Brookfield Renewable Partners will acquire all shares in Westinghouse Electric Company and upon completion Cameco will beneficially own a 49% interest and Brookfield Renewable, with its institutional partners, will beneficially own a 51% interest.

Westinghouse has been active in the energy industry for over a century and today Westinghouse is an industry leader providing mission-critical and specialized technologies, products and services used in the nuclear energy sector. In Sweden, Westinghouse mainly operates through Westinghouse Electric Sweden AB and has around 800 employees in Sweden and an annual Swedish revenue of over SEK 3.0 billion. 

Cameco is one of the largest global providers of fuel used for nuclear energy, with extensive uranium mining and milling operations, as well as refining and conversion facilities and CANDU fuel fabrication for heavy water reactors.

Brookfield Renewable operates one of the largest publicly traded, pure-play renewable power platforms and is among the world’s largest investors in clean energy and transition assets, with approximately 125,000 MW of operating and development capacity worldwide.

Completion is subject to customary regulatory approvals.

The Vinge team, led by Peter Sundgren (M&A) and Johan Cederblad (Environmental and Nuclear Regulations), included Per Kling, Gustav Wahlberg and Robin Fagerström (M&A), Sara Strandberg (Employment), Stojan Arnerstål, Rebecka Målquist, Arvid Axelryd (IP), Hedvig Ekdahl and Mario Saad (Corporate Commercial), Anders Leissner and Victoria Gunnerek (International Trade) and Tove Tullberg (Compliance). In addition, Daniel Wendelsson, Sebastian Örndahl and Victoria Fredén is advising Cameco in connection with merger- and FDI filing.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025